Medtronic 670G insulin pump shows positive results in 7-13 year-olds

Medtronic has seen positive results after conducting an at-home study of its MiniMed 670G insulin pump system in children aged seven to 13 years with type 1 diabetes.

The latest findings mirror data from previous trials in adults and adolescents (14 and above), which showed positive effects for patients including less glycaemic variability and reduced exposure to hypoglycaemia and hyperglycaemia, compared to baseline data using sensor-augmented pumps.

Medtronic has made an application to the US Food and Drug Administration to make the MiniMed 670G system available to children between the ages of seven and 13 years. It is currently approved for people with type 1 diabetes aged 14 and over.

Data from trials involving children from two to six years of age is due to be published at a later date.

Discussing the results of the study involving seven to 13-year-olds, Dr Kevin Kaiserman, primary study investigator at the Southern California Diabetes Center, said: "I'm very pleased to see that the positive results observed in the pivotal trial studying older patients were also sustained in this study."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.